Skip to content

Discontinued — last reported Q4 '20

Total Revenue at other companies

Pfizer logo
PfizerPFE
$14.45B+5.4%
Amgen logo
AmgenAMGN
$8.62B+5.8%
Incyte logo
IncyteINCY
$1.27B+20.9%
CG Oncology logo
CG OncologyCGON
Scholar Rock logo
Scholar RockSRRK
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The official record: Cogent Biosciences, Inc.’s 10-K, filed March 15, 2022, on SEC EDGAR. View the filing →

Questions, answered.

What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.